50845-31-3

Upstream product

• 6315-89-5 3,4-dimethoxyaniline 
• 94-05-3 ethyl (ethoxymethylene)cyanoacetate 
• 30199-65-6 2-cyano-3-(3,4-dimethoxyphenylamino)acrylic acid ethyl ester 
• 5392-10-9 2-bromo-4,5-dimethoxybenzaldehyde 
• 50-00-0 formaldehyd 
• 26759-46-6 methyl 2-amino-4,5-dimethoxybenzoate 
• 20428-58-4 α-lithioacetonitrile 
• 75-05-8 acetonitrile 

Downstream Products

• 214470-55-0 4-chloro-6,7-dimethoxyquinoline-3-carbonitrile 
• 1458087-93-8 (3-amino-7,8-dimethoxythieno[3,2-c]quinolin-2-yl)(4-fluorophenyl)methanone 
• 1458088-20-4 methyl 7,8-dimethoxy-3-(4-methoxybenzamido)thieno[3,2-c]quinoline-2-carboxylate 
• 1458088-28-2 methyl 7,8-dimethoxy-3-(2-nitrobenzamido)thieno[3,2-c]quinoline-2-carboxylate 
• 331662-50-1 4-((2,4-dichlorophenyl)amino)-6,7-dimethoxyquinoline-3-carbonitrile 
• 214486-14-3 4-[3-(thiomethyl)phenylamino]-6,7-dimethoxy-3-quinolinecarbonitrile 
• 214484-24-9 4-(cyclohexylamino)-6,7-dimethoxy-3-quinolinecarbonitrile 
• 214484-30-7 4-[(methylphenyl)amino]-6,7-dimethoxy-3-quinolinecarbonitrile 

Relevant academic research and scientific papers

Copper-Catalyzed Synthesis of Substituted 4-Quinolones using Water as a Benign Reaction Media: Application for the Construction of Oxolinic Acid and BQCA

A copper-catalyzed three-component synthetic method has been developed for the synthesis of substituted 4-quinolone derivatives from substituted 3-(2-halophenyl)-3-oxopropane, aldehydes and aq. NH3 using water as an environmentally benign reaction media. Moreover, the synthetic utility of the obtained products has been successfully applied for the synthesis of available oxolinic acid and BQCA drugs. The key features of this approach include commercially available starting materials, broad scope, and moderate to good reaction yields. Reaction with formaldehyde, and other functionalities such as ?CN, ?NO2, ?SO2Ar, and ?COAr were also successful. In addition, reaction with heterocyclic compounds such as 3-(3-bromothiophen-2-yl)-3-oxopropanenitrile proceeded smoothly to afford tetrahydrothieno[3,2-b]pyridine-6-carbonitrile analogues. The practicality of the designed protocol was confirmed by gram scale synthesis of two derivatives. (Figure presented.).

Discovery of Multitarget Antivirals Acting on Both the Dengue Virus NS5-NS3 Interaction and the Host Src/Fyn Kinases

This study describes the discovery of novel dengue virus inhibitors targeting both a crucial viral protein-protein interaction and an essential host cell factor as a strategy to reduce the emergence of drug resistance. Starting from known c-Src inhibitors

3-AMINOTHIENO[3,2-c]QUINOLINE DERIVATIVES, METHODS OF PREPARATION AND USES

The present invention relates to compounds according to Formula I: and salts thereof, wherein R1, R2, R3, R4, R5, R6, R7, X, and Y are as defined herein. Methods for preparing co

Dibenzonaphthyridine derivatives and methods of use thereof

The present invention relates to Dibenzonaphthyridine Derivatives, compositions comprising an effective amount of a Dibenzonaphthyridine Derivative and methods for treating or preventing a proliferative disorder, comprising administering to a subject in need thereof an effective amount of a Dibenzonaphthyridine Derivative.

An efficient synthesis of dibenzo[c,f]-2,7-naphthyridine ring system through design of experiments

The dibenzo[c,f]-2,7-naphthyridine ring system was found to be of biological interest, but had limited synthetic accessibility. The initial compound of interest, 10,11-dimethoxy-4-methyldibenzo[c,f]-2,7-naphthyridine-3, 6-diamine, was obtained in 25% yie

AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS

The invention is directed to aminoquinoline and aminoquinazoline compounds of Formula I: where R1, R2, R3, B, Z, Q, p, q and X are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of FLT3 and/or TrkB, the use of such compounds to reduce or inhibit kinase activity of FLT3 and/or TrkB in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to FLT3 and/or TrkB. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.

ANTIVIRAL AGENTS

Compounds are provided having utility for the treatment of viral infections, particularly HCV.

SYNERGISTIC MODULATION OF FLT3 KINASE USING AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS

The invention is directed to a method of inhibiting FLT3 tyrosine kinase activity or expression or reducing FLT3 kinase activity or expression in a cell or a subject comprising the administration of a farnesyl transferase inhibitor and a FLT3 kinase inhibitor selected from aminoquinoline and aminoquinazoline compounds of Formula I′: where R1, R2, R3, B, Z, Q, p, q and X are as defined herein. Included within the present invention is both prophylactic and therapeutic methods for treating a subject at risk of (or susceptible to) developing a cell proliferative disorder or a disorder related to FLT3.

USE OF CYANOQUINOLINES FOR TREATING OR INHIBITING COLONIC POLYPS

This invention provides a method of treating or inhibiting colonic polyps which comprises providing a compound of formula (1); wherein R1, R2, R3, R4, X, Y, and n are defined hereinbefore, or a pharmaceutically acceptable salt thereof.